BioAge Labs, Inc Market Cap ($273.55 Million)
Market Cap & Net Worth: BioAge Labs, Inc (BIOA)
BioAge Labs, Inc market cap. BioAge Labs, Inc (NASDAQ:BIOA) has a market capitalization of $273.55 Million ($273.55 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14977 globally and #3573 in its home market, demonstrating a 19.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioAge Labs, Inc's stock price $5.96 by its total outstanding shares 45896909 (45.90 Million). Also see BIOA cash generation efficiency for how efficiently the company converts equity into cash flow.
BioAge Labs, Inc Market Cap History (2024–2026)
BioAge Labs, Inc market cap history from 2024 to 2026. Data shows change from $265.74 Million to $273.55 Million (-41.34% CAGR). Check BioAge Labs, Inc stock quote for real-time trading data and today's change.
Index Memberships
BioAge Labs, Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #397 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1458 of 3165 |
Weight: BioAge Labs, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioAge Labs, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioAge Labs, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BioAge Labs, Inc (BIOA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
67.51x
BioAge Labs, Inc's market cap is 67.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $607.22 Million | $8.99 Million | -$80.61 Million | 67.51x | N/A |
Competitor Companies of BIOA by Market Capitalization
Companies near BioAge Labs, Inc in the global market cap rankings as of November 4, 2026. Also see BioAge Labs, Inc total assets for a full breakdown of the balance sheet.
Key companies related to BioAge Labs, Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of BioAge Labs, Inc (2024–2026)
Market capitalization of BioAge Labs, Inc from 2024 to today. Between 2024 and today, BioAge Labs, Inc's market cap moved from $265.74 Million to $ 273.55 Million, with a yearly change of -41.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $273.55 Million | -54.95% |
| 2025 | $607.22 Million | +128.50% |
| 2024 | $265.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of BioAge Labs, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $273.55 Million USD |
| MoneyControl | $273.55 Million USD |
| MarketWatch | $273.55 Million USD |
| marketcap.company | $273.55 Million USD |
| Reuters | $273.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more